{
  "input": {
    "mode": "report_and_evolve",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "hypotheses": [
      {
        "id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        },
        "mechanism_outline": "",
        "priority": 1.0
      },
      {
        "id": "H2",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "mechanism_outline": "",
        "priority": 0.95
      },
      {
        "id": "H3",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "mechanism_outline": "",
        "priority": 0.9
      },
      {
        "id": "H4",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "mechanism_outline": "",
        "priority": 0.85
      },
      {
        "id": "H5",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "mechanism_outline": "",
        "priority": 0.8
      },
      {
        "id": "H6",
        "candidate": {
          "id": "drug_ixekizumab",
          "name": "Ixekizumab"
        },
        "mechanism_outline": "",
        "priority": 0.75
      },
      {
        "id": "H7",
        "candidate": {
          "id": "drug_austedo",
          "name": "Austedo"
        },
        "mechanism_outline": "",
        "priority": 0.7
      },
      {
        "id": "H8",
        "candidate": {
          "id": "drug_methotrexate",
          "name": "Methotrexate"
        },
        "mechanism_outline": "",
        "priority": 0.6499999999999999
      },
      {
        "id": "H9",
        "candidate": {
          "id": "drug_cyclosporine",
          "name": "Cyclosporine"
        },
        "mechanism_outline": "",
        "priority": 0.6
      },
      {
        "id": "H10",
        "candidate": {
          "id": "drug_tildrakizumab",
          "name": "Tildrakizumab"
        },
        "mechanism_outline": "",
        "priority": 0.55
      },
      {
        "id": "H11",
        "candidate": {
          "id": "drug_brodalumab",
          "name": "Brodalumab"
        },
        "mechanism_outline": "",
        "priority": 0.5
      },
      {
        "id": "H12",
        "candidate": {
          "id": "drug_ustekinumab",
          "name": "Ustekinumab"
        },
        "mechanism_outline": "",
        "priority": 0.44999999999999996
      }
    ],
    "scores": [
      {
        "hypothesis_id": "H1",
        "score": 0.48,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.3,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.5
        },
        "graph_signals": {
          "support_weight": 0.75,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Acitretin Risks",
              "pro": [
                "n_adv_acitretin"
              ],
              "con": [
                "H1"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Acitretin作用于IL-17A，并与病理状态关联"
          ],
          "safety_risk": [
            "存在较强的副作用风险，Skeptic指出可能导致不良表型"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Acitretin的长期安全性需进一步评估"
        ]
      },
      {
        "hypothesis_id": "H2",
        "score": 0.48,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.3,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.5
        },
        "graph_signals": {
          "support_weight": 0.75,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Adalimumab Risks",
              "pro": [
                "n_adv_adalimumab"
              ],
              "con": [
                "H2"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Adalimumab靶向TNF-alpha，减少炎症"
          ],
          "safety_risk": [
            "副作用风险较高，存在可能导致不良表型的担忧"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Adalimumab的长期效果与安全性需进一步验证"
        ]
      },
      {
        "hypothesis_id": "H3",
        "score": 0.48,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.3,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.5
        },
        "graph_signals": {
          "support_weight": 0.75,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Etanercept Risks",
              "pro": [
                "n_adv_infliximab"
              ],
              "con": [
                "H3"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Etanercept靶向TNF-alpha，缓解炎症"
          ],
          "safety_risk": [
            "存在较强副作用风险，可能影响应用价值"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Etanercept的真实疗效尚待更多数据支持"
        ]
      },
      {
        "hypothesis_id": "H4",
        "score": 0.48,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.3,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.5
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Infliximab Risks",
              "pro": [
                "n_adv_infliximab"
              ],
              "con": [
                "H4"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Infliximab抑制TNF-alpha发挥作用"
          ],
          "safety_risk": [
            "存在较强副作用，Skeptic表明可能导致不良反应"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Infliximab的使用安全性尚需验证"
        ]
      },
      {
        "hypothesis_id": "H5",
        "score": 0.48,
        "components": {
          "mechanism_fit": 0.7,
          "class_prior": 0.6,
          "pk_pd_feasibility": 0.5,
          "indication_plausibility": 0.5,
          "safety_risk": 0.3,
          "graph_bonus": 0.15,
          "conflict_penalty": 0.5
        },
        "graph_signals": {
          "support_weight": 0.7,
          "contradiction_weight": 0.8,
          "mechanistic_connectivity": false,
          "path_disjointness": 1,
          "conflict_hotspots": [
            {
              "topic": "Secukinumab Risks",
              "pro": [
                "n_adv_secukinumab"
              ],
              "con": [
                "H5"
              ]
            }
          ]
        },
        "rationales": {
          "mechanism_fit": [
            "Secukinumab特异性抑制IL-17A"
          ],
          "safety_risk": [
            "与潜在风险相结合，可能导致不良表型"
          ]
        },
        "confidence": "medium",
        "uncertainties": [
          "Secukinumab的疗效与安全性待进一步解析"
        ]
      },
      {
        "hypothesis_id": "H6",
        "score": 0.35,
        "confidence": "medium",
        "uncertainties": [
          "Ixekizumab的有效性与安全性仍待进一步调查"
        ]
      },
      {
        "hypothesis_id": "H7",
        "score": 0.1,
        "confidence": "low",
        "uncertainties": [
          "Austedo与此疾病的相关性未证明，疗效不确定"
        ]
      },
      {
        "hypothesis_id": "H8",
        "score": 0.25,
        "confidence": "low",
        "uncertainties": [
          "Methotrexate对皮肤病的疗效在此情况下不明确"
        ]
      },
      {
        "hypothesis_id": "H9",
        "score": 0.25,
        "confidence": "low",
        "uncertainties": [
          "Cyclosporine在此情境下的作用尚需证实"
        ]
      },
      {
        "hypothesis_id": "H10",
        "score": 0.35,
        "confidence": "medium",
        "uncertainties": [
          "Tildrakizumab的疗效与安全性仍需进一步探讨"
        ]
      },
      {
        "hypothesis_id": "H11",
        "score": 0.3,
        "confidence": "low",
        "uncertainties": [
          "Brodalumab的效果较少数据支持"
        ]
      },
      {
        "hypothesis_id": "H12",
        "score": 0.3,
        "confidence": "low",
        "uncertainties": [
          "Ustekinumab在此病症下的应用效果尚待证实"
        ]
      }
    ],
    "ranking": [
      "H1",
      "H2",
      "H3",
      "H4",
      "H5",
      "H6",
      "H10",
      "H11",
      "H12",
      "H8",
      "H9",
      "H7"
    ],
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_austedo",
          "type": "Drug",
          "label": "Austedo",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_IL17A",
          "type": "Target",
          "label": "IL-17A",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_TNF_alpha",
          "type": "Target",
          "label": "TNF-alpha",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_skin_inflammation",
          "type": "Phenotype",
          "label": "Skin Inflammation Phenotype",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_acitretin",
          "type": "Target",
          "label": "OffTarget of Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_acitretin",
          "type": "Pathway",
          "label": "Risk Pathway for Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_acitretin",
          "type": "Phenotype",
          "label": "Adverse Effects of Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_adalimumab",
          "type": "Target",
          "label": "OffTarget of Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_adalimumab",
          "type": "Pathway",
          "label": "Risk Pathway for Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_adalimumab",
          "type": "Phenotype",
          "label": "Adverse Effects of Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_infliximab",
          "type": "Target",
          "label": "OffTarget of Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_infliximab",
          "type": "Pathway",
          "label": "Risk Pathway for Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_infliximab",
          "type": "Phenotype",
          "label": "Adverse Effects of Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_secukinumab",
          "type": "Target",
          "label": "OffTarget of Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_secukinumab",
          "type": "Pathway",
          "label": "Risk Pathway for Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_secukinumab",
          "type": "Phenotype",
          "label": "Adverse Effects of Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_acitretin",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Acitretin通过IL-17A调节免疫反应"
        },
        {
          "source": "drug_adalimumab",
          "target": "target_TNF_alpha",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "Adalimumab抑制TNF-alpha，减少炎症"
        },
        {
          "source": "drug_etanercept",
          "target": "target_TNF_alpha",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "Etanercept靶向TNF-alpha，缓解炎症"
        },
        {
          "source": "drug_infliximab",
          "target": "target_TNF_alpha",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "Infliximab通过抑制TNF-alpha发挥作用"
        },
        {
          "source": "drug_secukinumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Secukinumab特异性抑制IL-17A"
        },
        {
          "source": "drug_ixekizumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Ixekizumab靶向IL-17A以改善症状"
        },
        {
          "source": "drug_methotrexate",
          "target": "pathway_inflammatory_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Methotrexate在炎症通路中有作用"
        },
        {
          "source": "drug_cyclosporine",
          "target": "pathway_inflammatory_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Cyclosporine通过抑制免疫系统缓解炎症"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Tildrakizumab靶向IL-17A有效"
        },
        {
          "source": "drug_brodalumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Brodalumab靶向IL-17A以改善临床症状"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Ustekinumab抑制IL-17及IL-23"
        },
        {
          "source": "target_IL17A",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "IL-17A在炎症反应通路中重要"
        },
        {
          "source": "target_TNF_alpha",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "TNF-alpha在炎症反应通路中关键"
        },
        {
          "source": "pathway_inflammatory_response",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "causes",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "炎症反应通路与病理状态关联"
        },
        {
          "source": "drug_acitretin",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Acitretin已用于治疗该状态"
        },
        {
          "source": "drug_adalimumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Adalimumab显示出疗效"
        },
        {
          "source": "drug_etanercept",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Etanercept用作治疗选项"
        },
        {
          "source": "drug_infliximab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Infliximab用于该病的治疗"
        },
        {
          "source": "drug_secukinumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Secukinumab治疗显示帮助"
        },
        {
          "source": "drug_ixekizumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "Ixekizumab在这一状态下得到了认可"
        },
        {
          "source": "drug_methotrexate",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "Methotrexate用于治疗皮肤疾病"
        },
        {
          "source": "drug_cyclosporine",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "Cyclosporine有时用于此类疾病"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "Tildrakizumab已显示效果"
        },
        {
          "source": "drug_brodalumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "Brodalumab被探索用于此病症"
        },
        {
          "source": "drug_ustekinumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "Ustekinumab对相关症状有帮助"
        },
        {
          "source": "drug_acitretin",
          "target": "n_ot_acitretin",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在的旁路影响"
        },
        {
          "source": "n_ot_acitretin",
          "target": "n_rp_acitretin",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路风险关联"
        },
        {
          "source": "n_rp_acitretin",
          "target": "n_adv_acitretin",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致不良表型"
        },
        {
          "source": "n_adv_acitretin",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "风险成立将抵消益处"
        },
        {
          "source": "drug_adalimumab",
          "target": "n_ot_adalimumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在的旁路影响"
        },
        {
          "source": "n_ot_adalimumab",
          "target": "n_rp_adalimumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路风险关联"
        },
        {
          "source": "n_rp_adalimumab",
          "target": "n_adv_adalimumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致不良表型"
        },
        {
          "source": "n_adv_adalimumab",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "风险成立将抵消益处"
        },
        {
          "source": "drug_infliximab",
          "target": "n_ot_infliximab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在的旁路影响"
        },
        {
          "source": "n_ot_infliximab",
          "target": "n_rp_infliximab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路风险关联"
        },
        {
          "source": "n_rp_infliximab",
          "target": "n_adv_infliximab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致不良表型"
        },
        {
          "source": "n_adv_infliximab",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "风险成立将抵消益处"
        },
        {
          "source": "drug_secukinumab",
          "target": "n_ot_secukinumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在的旁路影响"
        },
        {
          "source": "n_ot_secukinumab",
          "target": "n_rp_secukinumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路风险关联"
        },
        {
          "source": "n_rp_secukinumab",
          "target": "n_adv_secukinumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致不良表型"
        },
        {
          "source": "n_adv_secukinumab",
          "target": "H5",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "风险成立将抵消益处"
        }
      ],
      "round_index": 4
    },
    "history": {
      "round": 4
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65
    },
    "heuristic_priors": []
  },
  "output": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_acitretin",
          "name": "Acitretin"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "Acitretin作用于IL-17A并已被用于治疗",
          "潜在副作用风险需进一步验证"
        ],
        "caveats": [
          "副作用风险较高，长期效果不明确"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_adalimumab",
          "name": "Adalimumab"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "Adalimumab靶向TNF-alpha以减少炎症",
          "主要副作用风险需评估"
        ],
        "caveats": [
          "长期疗效与安全性需进一步验证"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_etanercept",
          "name": "Etanercept"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H3_round4",
        "key_assumptions": [
          "Etanercept靶向TNF-alpha并用于治疗此病",
          "副作用风险是否可接受需确认"
        ],
        "caveats": [
          "疗效尚需更多数据支持"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_infliximab",
          "name": "Infliximab"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H4_round4",
        "key_assumptions": [
          "Infliximab通过抑制TNF-alpha发挥作用",
          "与潜在副作用相关的风险需评估"
        ],
        "caveats": [
          "需进一步验证使用安全性"
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H5",
        "candidate": {
          "id": "drug_secukinumab",
          "name": "Secukinumab"
        },
        "score": 0.48,
        "graph_snapshot_ref": "GE_H5_round4",
        "key_assumptions": [
          "Secukinumab靶向IL-17A并显示帮助",
          "副作用风险需明确"
        ],
        "caveats": [
          "疗效与安全性待进一步解析"
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Target→Pathway→Disease",
          "reason": "主要候选药物靶向关键病理途径"
        }
      ],
      "remaining_gaps": [
        "副作用风险的具体评估",
        "长期疗效数据不足"
      ]
    },
    "seed_retrospective": {
      "batches": [
        {
          "round": 1,
          "seeds": [
            "A",
            "B",
            "C",
            "D"
          ],
          "impact_summary": "帮助识别出有效的靶点"
        }
      ],
      "lessons": [
        "需优先关注副作用风险的研究",
        "靶向IL-17A的药物需具备明确的有效性和安全性数据"
      ]
    },
    "prompt_patches": [],
    "heuristics": []
  }
}